Page 4 - Obesity

Obesity cure is here? Why it could be a win-win for all stakeholders

We Indians have had a different perspective around obesity

Scientists behind Ozempic and Wegovy win $3-million Breakthrough Prize

Five scientists who pioneered GLP-1-based drugs Ozempic and Wegovy receive $3 million Breakthrough Prize for life-changing contributions to diabetes and obesity treatment

Novo bets on Triple G obesity drug in up to $2 bn deal with Chinese biotech

Novo has been trying to strengthen its foothold in the potential $150 billion obesity market through the development of next-generation drugs, acquisitions and partnerships

Statsguru: Obesity, a pandemic in the making, may hit India hard by 2050

The number of Indian obese adults increased from 5.76 million in 1991 to 46.78 million in 2021; it is poised to reach 173.73 million by 2050

India's obesity crisis: Reorienting food policies can address the problem

Growing prosperity, urbanisation, and sedentary lifestyles are out of sync with Indian cuisine, undoubtedly among the world's most delicious but traditionally suited for manual work

World Obesity Day 2025: Theme, history, significance, habits and more

Every year on March 4, people mark World Obesity Day with the goal of eradicating stigma and misconceptions regarding obesity and increasing public awareness about it

AbbVie enters obesity drug market with up to $2.2 billion Gubra deal

The licensing deal could set the US drugmaker to vie with Eli Lilly & Co. and Novo Nordisk A/S, the current leaders in a market that's expected to reach $130 billion in annual sales by 2030

Biocon launches drug Liraglutide for diabetes, Biolide for obesity in UK

Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK. The GLP-1 peptide, Liraglutide, will be marketed in the UK under the brand names Liraglutide Biocon for diabetes and Biolide for chronic weight management, the company said in a statement. The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, earlier this year, making Biocon Ltd the first generics company to obtain approval for gLiraglutide in a major regulated market, it added. "The timely launch will offer healthcare providers and patients affordable access to this drug and help fulfil an unmet need," Biocon CEO and MD Siddharth Mittal said. The company will continue to focus its efforts towards expanding the reach of gLiraglutide into other European markets, the US and select geographies, he added. Glucagon-like peptide-1 (GLP-1) are medications that help lower blood sugar levels and promote weight loss. Liraglutid

PM Modi picks Omar Abdullah, 9 others for nationwide anti-obesity drive

PM Modi nominates Omar Abdullah, 9 others for anti-obesity campaign, urging for a nationwide movement to reduce oil consumption and promote a healthier India

Global pharma eyes India's obesity mkt, but weight-loss drugs face hurdles

These drugs belong to a class known as glucagon-like peptide receptor agonists (GLP-1RAs), which mimic a natural hormone that helps regulate blood sugar and appetite

PM Modi's push for obesity fight draws praise from medical fraternity

Co-Chair of the CII Public Health Council and Director of ITC Healthcare, Dr Sunil Chandy, said that the Prime Minister's obesity is the new epidemic that is affecting the Indian population

Proposed obesity benchmark adds organ health, daily functionality metrics

The recommendation signals a long-awaited shift from a single imperfect metric toward a more personalised diagnosis

Dr Morepen forays into wellness segment with weight management initiative

Dr Morepen on Tuesday forayed into the growing wellness segment with the launch of a weight management initiative. The company, a fully-owned subsidiary of Morepen Laboratories, is looking to establish itself in the segment which is currently valued at around Rs 12,000 crore and growing at an annual rate of 16 per cent. The company has launched its wellness product -- LightLife -- designed to tackle India's growing obesity crisis. India's obesity rate is increasing and this segment is expected to touch USD 52.3 billion by 2032, "reflecting the urgency to address weight management with solutions that are both safe and effective," Dr Morepen CEO Varun Suri said. With LightLife the company is looking to address the obesity issue without crash diets or harmful fads, he stated. According to the World Obesity Atlas 2024, over 25 per cent of Indian adults are projected to face obesity by 2035. Suri said the company's initiative is about promoting a healthy balanced lifestyle through ...

Eli Lilly to launch its obesity drug at competitive price in India in 2025

Lilly's rival Danish firm Novo Nordisk is also working to bring its obesity drug Wegovy (Semaglutide) to India soon, and according to reports the company may launch Wegovy in 2026

Eli Lilly to boost weight-loss drug supply with $3 billion expansion

The company's s blockbuster weight-loss and diabetes drugs have made it the most valuable pharmaceutical company in the world

Lilly's tirzepatide challenges semaglutide in obesity drug market

The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem

Need to recognise obesity as chronic disease for better management: Experts

There is a disconnect between awareness, understanding and management of obesity and recognising it as a chronic disease will be the first step towards obesity management, experts have said. A recent report by global healthcare company Novo Nordisk, that involved more than 2,000 people living with obesity (PwO) and 300 healthcare professionals in India, underlined the need for an integrated, long-term approach to the treatment of obesity. PwO face immense difficulties in maintaining weight loss and more than half of those surveyed said they reverted to old eating habits despite their efforts to change. More than 44 per cent regain lost weight within six months, the report said, emphasising the need for more sustainable, long-term solutions that go beyond just lifestyle adjustments. "The first step towards obesity management is to understand that it is a chronic disease. We need to support People with Obesity (PwO) with tools that not only help them lose weight but also maintain tha

Novo Nordisk posts Q3 sales of obesity drug Wegovy above expected forecast

The Denmark-based company said it now expects sales growth this year of between 23% and 27% in local currencies, compared to the previously guided range for 22% to 28% growth

Obesity medicines would cost US medicare $35 billion through 2034

Expanding coverage of weight-loss drugs like blockbusters from Eli Lilly & Co. and Novo Nordisk A/S would make 12.5 million more people in the US program eligible

EU regulator backs use of Novo's Wegovy for obesity related heart condition

It also improved physical limitations and exercise function in patients with the condition, Novo said